Original from: business wire
Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa) and Sysmex Corporation (President: Kaoru Asano) today announced that they have entered into an agreement to expand their Contract Development and Manufacturing Organization (CDMO) partnership for Sysmex's Automated Immunoassay System HISCL™-Series to include the field of neurodegenerative diseases, following the discussion based on the Basic Agreement on Business Collaboration in the field of immunoassay signed in October 2023.
While Fujirebio has been developing dedicated reagents for Sysmex¡¯s HISCL™-Series since 2020, the two companies agreed in October 2023 to deepen their partnership, based on a common belief that combining their respective expertise and strengths in immunoassay will accelerate their global expansion, and will contribute to the development and advancement of immunoassay. Since then, the two companies have been discussing how to strengthen their collaboration.
Under the terms of the new agreement, in the field of neurodegenerative diseases including Alzheimer's Disease, Fujirebio will develop reagents for Sysmex's HISCL™-Series for cerebral spinal fluid (CSF)-based testing as well as blood-based testing. This will accelerate the expansion of Sysmex¡¯s testing parameters in the diseases field, further propelling the expansion of its global footprint in immunoassay.
Fujirebio and Sysmex will further collaborate to develop and launch the tests as early as possible.
